The American Journal of Managed Care

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

INCA033989 targets CALR mutations, showing efficacy in engineered cell lines and mouse models of MPNs, without affecting other cells. CALR mutations are significant in JAK2V617F-negative essential ...
Business Wire

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential ...

The FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive ...
Hosted on MSN

Incyte's rare blood cancer therapy gets FDA's breakthrough status

Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with ...
Nasdaq

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...
Business Wire

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class ...